Biogen Appoints Jane Grogan, Ph.D., as Executive Vice President and Head of Research & Development

On September 6, Biogen announced that it would appoint Dr. Jane Grogan as Executive Vice President and Head of the Research and Development Department, effective October 2, 2023. At the same time, Jane Grogan will also become a member of Biogen's Executive Committee, reporting directly to President and Chief Executive Officer Christopher A. Viehbacher.

Jane Grogan has nearly 20 years of leadership experience in biotechnology research. She worked at Genentech for 15 years, during which time, as the lead scientist in cancer immunology research, she conducted in-depth studies on T-cell activation, tolerance induction, and epigenetic regulatory mechanisms through an integrated approach combining bioinformatics, biology, and diagnostics. She identified key regulators of effector T cells and regulatory T cells and advanced several targets into clinical research for autoimmune and cancer indications, such as TNF-α for rheumatoid arthritis and TIGIT for cancer immunotherapy. During her time at Genentech, she was also responsible for strategic integration between early discovery, clinical development, and business development, and served as the project leader for engineered T-cell therapy.

Jane Grogan also served as the Chief Scientific Officer of cell and gene editing company Graphite Bio. Not only that, she also served as the Chief Scientific Officer of T-cell therapy company ArsenalBio, overseeing research, discovery, and preclinical pipelines, including the development of the company's first candidate product.

Viehbacher stated, "Dr. Grogan is a pioneering scientist whose groundbreaking discoveries at Genentech have paved the way for the development of targeted therapies in autoimmune and oncology fields. I believe she will be a valuable asset to Biogen as we seek to bring more innovative drugs to market faster and more efficiently. She will work with Dr. Priya Singhal, Executive Vice President and Head of Development, to define the company’s portfolio strategy and make decisions on our scientific expertise and translational capabilities."

In recent years, Biogen's overall revenue has been affected by the fluctuating decline in sales of its multiple sclerosis (MS) business and repeated setbacks in the development of innovative drugs like Aduhelm, leading to continuous negative news about layoffs and pipeline cuts. It is hoped that the addition of Jane Grogan will bring new opportunities to Biogen.

Copyright © 2023 PHARMCUBE. All Rights Reserved.

Welcome to forward, share, and reasonably cite. When citing, please clearly indicate the source of the article; if you need to reprint, please leave a message to the WeChat Official Account backend or send a message, and specify the name and ID of the official account.

Disclaimer: The information in this WeChat article is for general reference only and should not be directly used as decision-making content. PharmaCube assumes no responsibility for any loss incurred by any party due to the use of the content herein.